ProQR Therapeutics N.V. Stock
ProQR Therapeutics N.V. Stock
ProQR Therapeutics N.V. shows a slight decrease today, losing -€0.004 (-0.270%) compared to yesterday.
ProQR Therapeutics N.V. is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
With a target price of 6 € there is potential for a 307.61% increase which would mean more than doubling the current price of 1.47 € for ProQR Therapeutics N.V..
Our community identified positive and negative aspects for ProQR Therapeutics N.V. stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the ProQR Therapeutics N.V. stock. On the other hand our users think that "Company culture" could be a problem in the future.
Pros and Cons of ProQR Therapeutics N.V. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ProQR Therapeutics N.V. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ProQR Therapeutics N.V. | -0.270% | -4.686% | 28.512% | 2.588% | -8.031% | -45.119% | -63.538% |
| Pharming Group | -0.300% | -2.094% | 1.878% | 71.104% | -5.108% | 25.788% | 17.200% |
| Formycon AG | 1.960% | -1.728% | -17.527% | -30.054% | -24.305% | -72.951% | -67.659% |
| Heron Therapeutics Inc. | 3.360% | -9.054% | -19.476% | -63.319% | -29.668% | -64.362% | -94.461% |
Comments
ProQR Therapeutics (PRQR) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $9.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics N.V. (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat